Nicolas Marcoux MD, FRCPC
@NickMarcouxMD
Followers
435
Following
1K
Statuses
432
Med onc and hematologist at @chudequebec with focus on lung cancer. Tweets in English for sake of conversation, mais toujours heureux de parler français!
Québec, Canada
Joined February 2017
RT @StephenVLiu: Phase I study of TY-9591 (asandeutertinib) for #EGFR NSCLC @JTOonline. Asandeutertinib is a deuterium stabilized osimertin…
0
20
0
Un hommage bien mérité pour un collègue d’exception. Un mentor depuis ma première année de médecine, avec qui j’ai la chance de travailler au quotidien maintenant! Merci pour tout ce que tu fais pour les patients au quotidien
1
0
2
Merci @NormandBlais de mettre en valeur notre belle gang! On est une grande famille qui traitons le cancer du poumon au Québec et le RESOT n’existerait pas sans ton implications #clcco #lcsm
0
1
12
RT @StephenVLiu: Results from TROPION-Lung05 @JCO_ASCO: single arm phase II trial of datopotamab deruxtecan (TROP2 ADC) in NSCLC with an ac…
0
12
0
RT @DrYukselUrun: 🧬🩸Exciting update! LB-RECIST introduces a new era for evaluating tumor response using liquid biopsy (ctDNA), addressing l…
0
70
0
RT @StephenVLiu: Will have to wait a bit longer for subcutaneous amivantamab. FDA issues complete response letter to application - not base…
0
11
0
RT @teachplaygrub: 1/Do radiologists sound like they are speaking a different language when they talk about MRI? T1 shortening what? T2 p…
0
973
0
The end of DD-MVAC? For me yes! Long live periop cis-gem-durva in MIBC (until we do even better!) Great talk by @tompowles1 as usual! #ESMO24
1
0
3
Always nice to see @CDNCancerTrials trials on the big stage, even when the results are not what everyone wished for… good job to all the investigators #lcsm #ESMO2024
0
0
2
RT @StephenVLiu: Two cases of de novo #SCLC with #EGFR exon 20 insertions highlight challenges of the current era - both cases had some res…
0
19
0
RT @StephenVLiu: Myopathy is an underappreciated toxicity of the #EGFR TKI osimertinib. In my experience, more of a later event. In this @J…
0
17
0
While many of us are still amazed by the updated PFS results from CROWN, important data included regarding outcomes after dose adjustment . Tox can be tricky, individualizing the dose is important! #ASCO24
0
1
5
RT @jillfeldman4: As we anxiously await data to read out at #ASCO24, please remember, People Come First! @MaryBoulanger4 will present her w…
0
17
0
À nouveau cette année conférence mémorable de Dre Marie-Anne Archambault Grenier! Nouvelle tradition? @AMHOQ_org
0
0
6
Entendu en cette journée mémorable au Mont Mégantic: “bon ben j’ai vu la plus belle chose que je vais voir de ma vie… et j’ai juste 15 ans” Sans mot devant l’éclipse totale 🌙
0
0
5
RT @ManuelDomine: Flaura-2 Second interim Overall Survival analysis witha maturity of 41%. 3 years OS 64% vs 50% HR 0, 70. #ELCC2024 @Onc…
0
7
0